Literature DB >> 7840313

Identification of gastrin as a growth peptide in human pancreatic cancer.

J P Smith1, A P Fantaskey, G Liu, I S Zagon.   

Abstract

The present study reports the first evidence that the gastrointestinal peptide gastrin stimulates the growth of several human pancreatic cancer cells in culture and in tumors transplanted to nude mice. Gastrin promoted growth of all cell lines tested at a dose comparable to the binding affinity, providing evidence for a physiologically relevant receptor. The stimulatory effects of gastrin were blocked by the CCK-B/gastrin receptor antagonist L-365,260 and not by the CCK-A receptor antagonist L-364,718. Growth of PANC-1 cells in culture were inhibited by L-365,260, suggesting that gastrin is tonically produced by PANC-1 cells for regulation of growth. Athymic nude mice bearing PANC-1 xenografts were treated for 24 days subcutaneously with either 1% bovine serum albumin (diluent), pentagastrin (1 mg/kg), or L-365,260 (1 mg/kg) twice daily. Tumors from the pentagastrin-treated mice were found to weigh more and have greater protein and DNA content than controls, whereas these values were all decreased in tumors of L-365,260-treated mice. Receptor binding capacity changed in tumors of animals treated with the peptide or antagonist, suggesting a regulatory process. Gastrin immunoreactivity was detected in a transplanted PANC-1 human tumor. These results identify gastrin as a potent trophic peptide that actively stimulates growth of human pancreatic cancer and does so through a CCK-B/gastrin-like receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840313     DOI: 10.1152/ajpregu.1995.268.1.R135

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  42 in total

1.  Role of endogenous cholecystokinin on growth of human pancreatic cancer.

Authors:  Gail L Matters; Christopher McGovern; John F Harms; Kevin Markovic; Krystal Anson; Calpurnia Jayakumar; Melissa Martenis; Christina Awad; Jill P Smith
Journal:  Int J Oncol       Date:  2010-12-24       Impact factor: 5.650

2.  Affinity maturation of antibodies assisted by in silico modeling.

Authors:  Rodrigo Barderas; Johan Desmet; Peter Timmerman; Rob Meloen; J Ignacio Casal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-23       Impact factor: 11.205

Review 3.  Cholecystokinin and pancreatic cancer: the chicken or the egg?

Authors:  Jill P Smith; Travis E Solomon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-31       Impact factor: 4.052

4.  Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo.

Authors:  Brian M Barth; Rahul Sharma; Erhan I Altinoğlu; Thomas T Morgan; Sriram S Shanmugavelandy; James M Kaiser; Christopher McGovern; Gail L Matters; Jill P Smith; Mark Kester; James H Adair
Journal:  ACS Nano       Date:  2010-03-23       Impact factor: 15.881

5.  Downregulation of the CCK-B receptor in pancreatic cancer cells blocks proliferation and promotes apoptosis.

Authors:  Kristin K Fino; Gail L Matters; Christopher O McGovern; Evan L Gilius; Jill P Smith
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-22       Impact factor: 4.052

6.  Randomized prospective trial of the effect of induced hypergastrinemia on the prevention of pancreatic atrophy after pancreatoduodenectomy in humans.

Authors:  Jin-Young Jang; Sun-Whe Kim; Joon-Koo Han; Sang-Jae Park; Youn-Chan Park; Young Joon Ahn; Yong-Hyun Park
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

7.  Effect of chronic endogenous hypergastrinaemia on pancreatic growth and carcinogenesis in the hamster.

Authors:  M Chu; E Kullman; J F Rehfeld; K Borch
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

Review 8.  Regulation of epithelial cell growth by ZBP-89: potential relevance in pancreatic cancer.

Authors:  Longchuan Bai; Craig Logsdon; Juanita L Merchant
Journal:  Int J Gastrointest Cancer       Date:  2002

9.  Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment.

Authors:  Nicholas Osborne; Rebecca Sundseth; Julian Burks; Hong Cao; Xunxian Liu; Alexander H Kroemer; Lynda Sutton; Allen Cato; Jill P Smith
Journal:  Cancer Immunol Immunother       Date:  2019-09-24       Impact factor: 6.968

10.  Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.

Authors:  Jill P Smith; Timothy K Cooper; Christopher O McGovern; Evan L Gilius; Qing Zhong; Jiangang Liao; Alfredo A Molinolo; J Silvio Gutkind; Gail L Matters
Journal:  Pancreas       Date:  2014-10       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.